September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Safety and complications of Intravitreal injections performed over 8 years at a tertiary eye centre in Singapore
Author Affiliations & Notes
  • Yanping Xu
    Ophthalmology, National Healthcare Group Eye Institute, Singapore, Singapore, Singapore
  • Colin S Tan
    Ophthalmology, National Healthcare Group Eye Institute, Singapore, Singapore, Singapore
  • Footnotes
    Commercial Relationships   Yanping Xu, None; Colin Tan, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3337. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yanping Xu, Colin S Tan; Safety and complications of Intravitreal injections performed over 8 years at a tertiary eye centre in Singapore. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3337.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There has been a rapid rise in the use of intravitreal injections such as anti-vascular endothelial growth factors (anti-VEGF), performed over the past few years for the treatment of ocular neovascular diseases. This study aims to review the systemic and ocular adverse events amongst patients treated at a tertiary eye centre over a period of 8 years and compare the rates to major randomized control trials.

Methods : A retrospective review of all intravitreal injections of anti-VEGF performed over an 8-year period at a tertiary eye care centre in Singapore was done. We report the frequency of systemic and ocular adverse events and compared it amongst the various anti-VEGF agents.

Results : A total of 14 001 intravitreal injections were performed on 2225 patients from January 1, 2007 to December 31, 2014, and this included 9992 bevacizumab (71.4%), 3306 ranibizumab (23.6%) and 703 aflibercept (5.0%) injections. The mean age of the patients in the study was 68.5 ± 11.8 years (median 68.0 years, range: 21 to 102 years). There were 1266 male and 959 female patients in this study. The majority of the patients in our study were of Asian descent, with 1715 (77.0%) Chinese, 182 (8.2%) Malay, 182 (8.2%) Indian and 146 (6.6%) of other races. Systemic complications related to treatment were: 26 (1.17%) deaths (from any cause), of which 11 (0.49%) were from fatal thromboembolic events, 7 (0.31%) non-fatal thromboembolic events and 2 (0.09%) serious nonocular hemorrhage. Ocular complications included 1 (0.007%) endopthalmitis, 3 (0.021%) traumatic cataracts and 1 (0.007%) retinal detachment. Overall, there was no statistical significance between rates of thromboembolic events and death between Ranibizumab (Lucentis), Bevacizumab (Avastin) and Aflibercept (Eylea).

Conclusions : The systemic and ocular complications associated with intravitreal injections among Asian patients at a tertiary eye centre are relatively low, and reflect the safety of the treatments. There is no significant difference between the rates of adverse events between different anti-VEGFs.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×